Prophylactic Valproic Acid Treatment Prevents Schizophrenia-Related Behaviour in Disc1-L100P Mutant Mice

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Lipina, Tatiana V ^a   Haque, Fahmida Nipa ^b   McGirr, Alexander ^a   Boutros, Paul C ^c   Berger, Thorsten ^d   Mak, Tak W ^d   Roder, John C ^a,e   Wong, Albert H C ^b,f  

^a MOUNT SINAI HOSPITAL   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; BRAIN STEM; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CORPUS STRIATUM; DELETION MUTANT; DISC1 GENE; DRUG EFFICACY; FRONTAL CORTEX; GENE; GENE EXPRESSION; GENOTYPE; GLIA CELL; HIPPOCAMPUS; LCN2 GENE; MOUSE; NONHUMAN; SCHIZOPHRENIA; SUBVENTRICULAR ZONE; TREATMENT RESPONSE;

ACUTE-PHASE PROTEINS; ANIMALS; ANTIMANIC AGENTS; BEHAVIOR, ANIMAL; CROSSES, GENETIC; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; HOMOZYGOTE; LIPOCALINS; LOCOMOTION; MICE; MICROSCOPY, CONFOCAL; MUTATION; NERVE TISSUE PROTEINS; NEUROGLIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS; PHENOTYPE; RNA; SCHIZOPHRENIA; VALPROIC ACID;

MUS;

EID: 84871295441     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051562     Document Type: Article

References (58)

1. Lewis DA, Levitt P (2002) Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25: 409-432. Epub 2002 Mar 2022k 2
2. Brandon NJ, Sawa A, (2011) Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci 12: 707-722.
3. Porteous DJ, Millar JK, Brandon NJ, Sawa A, (2011) DISC1 at 10: connecting psychiatric genetics and neuroscience. Trends Mol Med 17: 699-706.
4. Enomoto A, Asai N, Namba T, Wang Y, Kato T, et al. (2009) Roles of disrupted-in-schizophrenia 1-interacting protein girdin in postnatal development of the dentate gyrus. Neuron 63: 774-787.
5. Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, et al. (2009) Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 136: 1017-1031.
6. Kim JY, Duan X, Liu CY, Jang MH, Guo JU, et al. (2009) DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. Neuron 63: 761-773.
7. Lee FH, Fadel MP, Preston-Maher K, Cordes SP, Clapcote SJ, et al. (2011) Disc1 point mutations in mice affect development of the cerebral cortex. J Neurosci 31: 3197-3206.
8. Li W, Zhou Y, Jentsch JD, Brown RA, Tian X, et al. (2007) Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc Natl Acad Sci U S A 104: 18280-18285.
9. Ayhan Y, Abazyan B, Nomura J, Kim R, Ladenheim B, et al. (2011) Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neurobehavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders. Mol Psychiatry 16: 293-306.
10. Papaleo F, Lipska BK, Weinberger DR (2011) Mouse models of genetic effects on cognition: Relevance to schizophrenia. Neuropharmacology.
11. Clapcote SJ, Lipina TV, Millar JK, Mackie S, Christie S, et al. (2007) Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54: 387-402.
12. Gottesman, II, Gould TD, (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160: 636-645.
13. Lipina TV, Niwa M, Jaaro-Peled H, Fletcher PJ, Seeman P, et al. (2010) Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. Genes Brain Behav 9: 777-789.
14. Lipina TV, Kaidanovich-Beilin O, Patel S, Wang M, Clapcote SJ, et al. (2011) Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse 65: 234-248.
15. Brown SM, Clapcote SJ, Millar JK, Torrance HS, Anderson SM, et al. (2012) Synaptic modulators Nrxn1 and Nrxn3 are disregulated in a Disc1 mouse model of schizophrenia. Mol Psychiatry 17: 469.
16. Monti B, Polazzi E, Contestabile A, (2009) Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2: 95-109.
17. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, et al. (2006) Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci U S A 103: 1834-1839.
18. Berger T, Cheung CC, Elia AJ, Mak TW, (2010) Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis. Proc Natl Acad Sci U S A 107: 2995-3000.
19. Tremolizzo L, Doueiri MS, Dong E, Grayson DR, Davis J, et al. (2005) Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry 57: 500-509.
20. Semeralul MO, Boutros PC, Likhodi O, Okey AB, Van Tol HH, et al. (2006) Microarray analysis of the developing cortex. J Neurobiol 66: 1646-1658.
21. Dunning MJ, Smith ML, Ritchie ME, Tavare S, (2007) beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23: 2183-2184.
22. Cairns JM, Dunning MJ, Ritchie ME, Russell R, Lynch AG, (2008) BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics 24: 2921-2922.
23. Edwards D, (2003) Non-linear normalization and background correction in one-channel cDNA microarray studies. Bioinformatics 19: 825-833.
24. Lin SM, Du P, Huber W, Kibbe WA, (2008) Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 36: e11.
25. Boutros PC, Okey AB (2005) Unsupervised Pattern Recognition: An Introduction to the Whys and Wherefores of Clustering Microarray Data. Briefings in Bioinformatics 6: in press.
26. Willott JF, Tanner L, O'Steen J, Johnson KR, Bogue MA, et al. (2003) Acoustic startle and prepulse inhibition in 40 inbred strains of mice. Behav Neurosci 117: 716-727.
27. Zheng QY, Johnson KR, Erway LC, (1999) Assessment of hearing in 80 inbred strains of mice by ABR threshold analyses. Hear Res 130: 94-107.
28. Zuckerman L, Rimmerman N, Weiner I, (2003) Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia. Psychopharmacology (Berl) 169: 298-307.
29. Arguello PA, Gogos JA, (2006) Modeling madness in mice: one piece at a time. Neuron 52: 179-196.
30. Rodvold JJ, Mahadevan NR, Zanetti M, (2012) Lipocalin 2 in cancer: when good immunity goes bad. Cancer Lett 316: 132-138.
31. Zhao C, Deng W, Gage FH, (2008) Mechanisms and functional implications of adult neurogenesis. Cell 132: 645-660.
32. Harrison PJ, (1999) The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122: 593-624.
33. Schnieder TP, Dwork AJ, (2011) Searching for neuropathology: gliosis in schizophrenia. Biol Psychiatry 69: 134-139.
34. Lee S, Park JY, Lee WH, Kim H, Park HC, et al. (2009) Lipocalin-2 is an autocrine mediator of reactive astrocytosis. J Neurosci 29: 234-249.
35. Walker EF, Savoie T, Davis D, (1994) Neuromotor precursors of schizophrenia. Schizophr Bull 20: 441-451.
36. Lawrie SM, McIntosh AM, Hall J, Owens DG, Johnstone EC, (2008) Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr Bull 34: 330-340.
37. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, et al. (2009) Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull 35: 894-908.
38. Broome MR, Woolley JB, Tabraham P, Johns LC, Bramon E, et al. (2005) What causes the onset of psychosis? Schizophr Res 79: 23-34.
39. Perucca E, Tomson T, (2011) The pharmacological treatment of epilepsy in adults. Lancet Neurol 10: 446-456.
40. Kirkbride JB, Jones PB, (2011) The prevention of schizophrenia-what can we learn from eco-epidemiology? Schizophr Bull 37: 262-271.
41. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, et al. (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36: 71-93.
42. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, et al. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
43. Williams RS, Cheng L, Mudge AW, Harwood AJ, (2002) A common mechanism of action for three mood-stabilizing drugs. Nature 417: 292-295.
44. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, et al. (2007) Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 321: 892-901.
45. Chateauvieux S, Morceau F, Dicato M, Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010.
46. Marshall M, Rathbone J (2011) Early intervention for psychosis. Cochrane Database Syst Rev: CD004718.
47. Zuckerman L, Weiner I, (2003) Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation. Psychopharmacology (Berl) 169: 308-313.
48. Piontkewitz Y, Arad M, Weiner I, (2011) Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull 37: 1257-1269.
49. Flood DG, Choinski M, Marino MJ, Gasior M, (2009) Mood stabilizers increase prepulse inhibition in DBA/2NCrl mice. Psychopharmacology (Berl) 205: 369-377.
50. Umeda K, Suemaru K, Todo N, Egashira N, Mishima K, et al. (2006) Effects of mood stabilizers on the disruption of prepulse inhibition induced by apomorphine or dizocilpine in mice. Eur J Pharmacol 553: 157-162.
51. Insel TR, (2010) Rethinking schizophrenia. Nature 468: 187-193.
52. Schurov IL, Handford EJ, Brandon NJ, Whiting PJ, (2004) Expression of disrupted in schizophrenia 1 (DISC1) protein in the adult and developing mouse brain indicates its role in neurodevelopment. Mol Psychiatry 9: 1100-1110.
53. Camargo LM, Collura V, Rain JC, Mizuguchi K, Hermjakob H, et al. (2007) Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psychiatry 12: 74-86.
54. Bolton MM, Eroglu C, (2009) Look who is weaving the neural web: glial control of synapse formation. Curr Opin Neurobiol 19: 491-497.
55. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N, (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268: 10425-10432.
56. Delcourt N, Jouin P, Poncet J, Demey E, Mauger E, et al. (2005) Difference in mass analysis using labeled lysines (DIMAL-K): a new, efficient proteomic quantification method applied to the analysis of astrocytic secretomes. Mol Cell Proteomics 4: 1085-1094.
57. Choi J, Lee HW, Suk K, (2011) Increased plasma levels of lipocalin 2 in mild cognitive impairment. J Neurol Sci 305: 28-33.
58. Shoji H, Toyama K, Takamiya Y, Wakana S, Gondo Y, et al. (2012) Comprehensive behavioral analysis of ENU-induced Disc1-Q31L and-L100P mutant mice. BMC Res Notes 5: 108.